摘要
胞外-5’-核苷酸酶(ecto-5’-NT、 5’-NT、 eN、 CD73)是一种膜酶,其主要由AMP腺苷的胞外产物构成。Ecto-5''-NT是由多种类型的癌症细胞过表达,导致了肿瘤微环境腺苷浓度的提高。发现腺苷在癌症机理中也很重要,对抗肿瘤T细胞和巨噬细胞表现出较强的免疫抑制作用,促进心血管生成和细胞粘附。这些作用帮助细胞生长与发展。提示ecto-5’-NT的抑制导致肿瘤微环境中胞外腺苷浓度的降低,这将直接影响肿瘤细胞并致使肿瘤恶性细胞易受宿主防御系统的影响。此机制被提议为癌症治疗的有希望的新靶点。本综述的目的是为了探索ecto-5’-NT生化和结构特征,包括分子模拟活性部位的简要分析,分子模拟是评估这种酶的抑制是否能够确实代表治疗癌症的可行性策略的一种方法。对在癌症治疗期间可能被用作ecto-5’-NT靶点的已知抑制剂和可能的原型也进行了讨论。
关键词: 腺苷,癌症治疗,胞外-5’-核苷酸酶,酶抑制,新靶点,嘌呤信号。
Current Medicinal Chemistry
Title:Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study
Volume: 22 Issue: 15
Author(s): Patricia Frasson Corbelini, Fabricio Figueiro, Gustavo Machado das Neves, Saulo Andrade and Daniel Fabio Kawano, Ana Maria Oliveira Battastini and Vera Lucia Eifler-Lima
Affiliation:
关键词: 腺苷,癌症治疗,胞外-5’-核苷酸酶,酶抑制,新靶点,嘌呤信号。
摘要: Ecto-5’-nucleotidase (ecto-5’-NT, 5’-NT, eN, CD73) is a membrane ectoenzyme that is primarily responsible for the extracellular production of adenosine from AMP. Ecto-5'-NT is overexpressed in various types of cancer cells, leading to elevated concentrations of adenosine in the tumour microenvironment. Adenosine has also been found to be important in cancer pathogenesis, showing strong immunosuppressive effects over antitumour T cells and macrophages and promoting neovascularization and cell adherence. These actions support tumour growth and development. It has been suggested that the inhibition of ecto-5’-NT results in lower extracellular concentrations of adenosine within the tumour microenvironment, which would directly affect cancer cells and render malignant cells more susceptible to host defence systems. Such mechanisms are proposed to represent promising new targets for cancer therapy. The aim of this review is to explore the biochemical and structural features of ecto-5’-NT, including a brief analysis of its active site by molecular modelling, as a means of evaluating whether the inhibition of this enzyme does indeed represent a feasible strategy for treating cancer. Known inhibitors and possible prototypes that could be used to target ecto-5’-NT during cancer therapy are also discussed.
Export Options
About this article
Cite this article as:
Patricia Frasson Corbelini, Fabricio Figueiro, Gustavo Machado das Neves, Saulo Andrade and Daniel Fabio Kawano, Ana Maria Oliveira Battastini and Vera Lucia Eifler-Lima , Insights into Ecto-5’-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study, Current Medicinal Chemistry 2015; 22 (15) . https://dx.doi.org/10.2174/0929867322666150408112615
DOI https://dx.doi.org/10.2174/0929867322666150408112615 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design The Life and Death of Protein Kinase C
Current Drug Targets Multicomponent Reactions in Antimitotic Drug Discovery
Current Topics in Medicinal Chemistry Gene Therapy Using IL-12 Family Members in Infection, Auto-Immunity, and Cancer
Current Gene Therapy Lipid-based Nano-phytomedicines for Disease Treatment and Theranostic Applications
Current Nanomedicine Emerging Concepts in the Analysis of Mitochondrial Genome Instability
Current Genomics Angiogenesis: A Target for Cancer Therapy
Current Pharmaceutical Design Resistance to Radiotherapy and Targeted Molecular Therapies in Squamous Cell Carcinomas of the Head and Neck, Preclinical Data and New Approaches
Current Signal Transduction Therapy Synthesis and Biological Activity of Chiral Dihydropyrazole: Potential Lead for Drug Design
Mini-Reviews in Medicinal Chemistry Notch Signalling Pathways and Their Importance in the Treatment of Cancers
Current Drug Targets The Role of Emerging Genomics and Proteomics Technologies in Cancer Drug Target Discovery
Current Cancer Drug Targets Trabectedin (Yondelis®) as a Therapeutic Option in Gynecological Cancers: A Focus on its Mechanisms of Action, Clinical Activity and Genomic Predictors of Drug Response
Current Drug Targets Mouse Mutants of Relaxin, Insulin-Like 3 Peptide and their Receptors
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents ATP Citrate Lyase Inhibitors as Novel Cancer Therapeutic Agents
Recent Patents on Anti-Cancer Drug Discovery MicroRNAs in Cancer Stem Cells: New Regulators of Stemness
Current Pharmaceutical Design Fluorescent Molecular Imaging: Technical Progress and Current Preclinical and Clinical Applications in Urogynecologic Diseases
Current Molecular Medicine Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety Traditional Chinese Medicine Network Pharmacology in Cardiovascular Precision Medicine
Current Pharmaceutical Design Competition Between Tumor and Mononuclear Phagocyte System Causing the Low Tumor Distribution of Nanoparticles and Strategies to Improve Tumor Accumulation
Current Drug Delivery MALAT1 Promotes Tumorigenesis and Increases Cellular Sensitivity to Herceptin in HER2-positive Breast Cancer
Current Cancer Drug Targets